Skip to main content

Table 2 Treatment emergent adverse events occurring in ≥5% of patients

From: A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Adverse event term

All Grades

Grade 1 or 2

Grade 3 or 4

Patients

% patients (N = 47)

Patients

% patients (N = 47)

Number of cycles

% cycles (N = 194)

Patients

% patients (N = 47)

Number of cycles

% cycles (N = 194)

Blood and lymphatic system

 Anaemia

21

45%

15

32%

38

20%

6

13%

11

6%

 Febrile Neutropenia

4

9%

0

0%

0

0%

4

9%

5

3%

Gastrointestinal disorders

 Abdominal Pain

10

21%

10

21%

15

8%

0

0%

0

0%

 Diarrhoea

10

21%

8

17%

21

11%

2

4%

2

1%

 Dyspepsia

3

6%

3

6%

3

2%

0

0%

0

0%

 Mouth ulcer

3

6%

3

6%

4

2%

0

0%

0

0%

 Nausea

24

51%

24

51%

42

22%

0

0%

0

0%

 Vomiting

14

30%

14

30%

26

13%

0

0%

0

0%

General disorders

 Fatigue

22

47%

18

38%

53

27%

4

9%

4

2%

 Fever

4

9%

4

9%

4

2%

0

0%

0

0%

 Flu-like Symptoms

6

13%

6

13%

9

5%

0

0%

0

0%

Infections and infestations

 Bronchial Infection

4

9%

2

4%

7

4%

2

4%

2

1%

 Lung infection

7

15%

4

9%

6

3%

3

6%

3

2%

 Rhinitis infective

5

11%

5

11%

6

3%

0

0%

0

0%

 UTI

7

15%

6

13%

7

4%

1

2%

1

1%

Investigations

 ECG QTc interval prolonged

16

34%

14

30%

26

13%

2

4%

2

1%

 Neutropenia

22

47%

7

15%

37

19%

15

32%

28

14%

 Thrombocytopenia

18

38%

10

21%

53

27%

8

17%

20

10%

Metabolism and nutritional disorders

 Anorexia

13

48%

13

28%

24

12%

0

0%

0

0%

 Hypoalbuminemia

4

9%

4

9%

5

3%

0

0%

0

0%

 Hypokalaemia

5

11%

5

11%

5

3%

1

2%

1

1%

 Hypophosphatemia

3

6%

3

6%

4

2%

0

0%

0

0%

MSK and connective tissue

 Back Pain

3

6%

3

6%

3

2%

0

0%

0

0%

 Muscle cramps

3

6%

3

6%

3

2%

0

0%

0

0%

 Pain in extremity

4

9%

4

9%

4

2%

0

0%

0

0%

Nervous system disorders

 Headache

10

21%

8

17%

12

6%

0

0%

0

0%

Psychiatric disorders

 Depression

3

6%

2

4%

2

1%

0

0%

0

0%

Respiratory and thoracic disorders

 Cough

3

6%

3

6%

3

2%

0

0%

0

0%

 Dyspnoea

4

9%

4

9%

6

3%

0

0%

0

0%

  1. Adverse Events categorised and graded according to CTCAE v 4.03
  2. CTCAE National Cancer Institute Common Terminology for Adverse Events, ECG QTc electrocardiogram corrected QT interval, MSK musculoskeletal, UTI urinary tract infection